产品封面图

Anti-H_CTLA-4 hIgG1 Antibody(I

pilimumab)
收藏
  • 询价
  • 吉满生物
  • GM-27203AB
  • 2026年05月29日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    CTLA-4 or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. CTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA-4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA-4 binds CD80 and CD86 with greater affinity and avidity than CD28 thus enabling it to outcompete CD28 for its ligands. CTLA-4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. CTLA-4 is also found in regulatory T cells (Tregs) and contributes to their inhibitory function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • Generation of Antibody Molecules Through Antibody Engineering

      domains of the heavy (V H ) and light (V L ) chains. Effector functions are determined by constant C H 2 and C H 3 domains. The picture is based on the crystal structure of an intact IgG2 anti-canine lymphoma MAb231 ( 2 ) (pdb entry 1IGT). The drawing

    • ELISA Procedure for Measuring Serum Antibody Titer

      to the polystyrene microtiter plate first. The antiserum containing the anti-peptide antibody is then added to the well and allowed to bind. Finally, a second antibody, specific for the first antibody and labeled for detection, is added to the well and allowed

    • 【翻译】Development trends for monoclonal antibody cancer therapeutics

      ). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    上海优宁维生物科技股份有限公司
    2026年05月29日询价
    询价
    吉满生物科技(上海)有限公司
    2026年05月29日询价
    ¥7293
    武汉博欧特生物科技有限公司
    2025年07月08日询价
    询价
    北京阿斯雷尔生物技术有限公司
    2026年05月29日询价
    Anti-H_CTLA-4 hIgG1 Antibody(Ipilimumab)
    询价